AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12845215 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 10702455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg (Group T20)
Number of subjects: 60
Study 10702455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg (Group T40)
Number of subjects: 60
Study 10702455 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 4 mL (Group NS)
Number of subjects: 60
Study 9316597 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge with clinical nurse specialist transitional follow-up care (N = 44)
Number of subjects: 96
Study 9316597 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 52)
Number of subjects: 96
Study 8174947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 18
Study 8174947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) + Cisapride (20 mg twice daily)
Number of subjects: 18
Study 8174947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily)
Number of subjects: 18
Study 3985039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg daily)
Number of subjects: 12
Study 3985039 — intervention group
Group type: COMPARATOR
Intervention: Aerosol beclomethasone (16 puffs daily)
Number of subjects: 12
Study 29705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary implantable nitinol device (TIND)
Number of subjects: 2
Study 27136498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Number of subjects: 134
Study 27136498 — intervention group
Group type: COMPARATOR
Intervention: Sleep education control
Number of subjects: 134
Study 24727024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-competitive rivals at high fertility
Number of subjects: 34
Study 24727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-competitive rivals at high fertility
Number of subjects: 34
Study 24727024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-competitive rivals at low fertility
Number of subjects: 34
Study 24727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-competitive rivals at low fertility
Number of subjects: 34
Study 24727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testosterone levels
Number of subjects: 34
Study 23135583 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 94
Study 23135583 — intervention group
Group type: COMPARATOR
Intervention: W-pouch
Number of subjects: 94
Study 20928906 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA without resistance training (AA, n = 7)
Number of subjects: 31
Study 20928906 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA 3 h after resistance training (RT, n = 12)
Number of subjects: 31
Study 20928906 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA 5 min before resistance training (AART, n = 12)
Number of subjects: 31
Study 18349328 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation associated with mental illness stigma
Number of subjects: 24
Study 18349328 — intervention group
Group type: COMPARATOR
Intervention: Simulation not associated with mental illness stigma
Number of subjects: 24
Study 15620828 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 24
Study 15620828 — intervention group
Group type: COMPARATOR
Intervention: Intermittent dosing of piperacillin-tazobactam
Number of subjects: 24
Study 12807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer interpretation (CI) of EKGs
Number of subjects: 0
Study 12807810 — intervention group
Group type: COMPARATOR
Intervention: No computer interpretation (CI) of EKGs
Number of subjects: 0
Study 12807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct computer interpretation (CI) included
Number of subjects: 0
Study 12807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) provided
Number of subjects: 0
Study 12807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) presented with EKG
Number of subjects: 0
Study 12807810 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect computer interpretation (CI) not presented with EKG
Number of subjects: 0
Study 10227009 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day Tibolone
Number of subjects: 64
Study 10227009 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Tibolone
Number of subjects: 64
Study 10227009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8712192 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide and individual health education intervention
Number of subjects: 2394
Study 8712192 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 2394
Study 1905445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed food (group A)
Number of subjects: 46
Study 1905445 — intervention group
Group type: COMPARATOR
Intervention: Normal solid food (group B)
Number of subjects: 46
Study 6374680 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (2 x 6 mg daily)
Number of subjects: 15
Study 6374680 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (2 x 25 mg daily)
Number of subjects: 15
Study 6374680 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (2 x 50 mg daily)
Number of subjects: 15
Study 6374680 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study 30022544 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA gel (7.8% 5-aminolaevulinic acid)
Number of subjects: 52
Study 30022544 — intervention group
Group type: COMPARATOR
Intervention: MAL cream (16% methyl-aminolaevulinate)
Number of subjects: 52
Study 30022544 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA gel
Number of subjects: 52
Study 30022544 — intervention group
Group type: COMPARATOR
Intervention: MAL cream
Number of subjects: 52
Study 28731385 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids SIP smartER
Number of subjects: 74
Study 28731385 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 74
Study 27086243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 45
Study 27086243 — intervention group
Group type: COMPARATOR
Intervention: 10Hz rTMS
Number of subjects: 45
Study 27086243 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 25167977 — intervention group
Group type: COMPARATOR
Intervention: Whole milk (3.25% M.F.)
Number of subjects: 12
Study 25167977 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated milk beverage (based on milk macronutrients)
Number of subjects: 12
Study 25167977 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete milk protein (16g)
Number of subjects: 12
Study 25167977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (24g)
Number of subjects: 12
Study 25167977 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fat (16g)
Number of subjects: 12
Study 21557778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled pen
Number of subjects: 421
Study 21557778 — intervention group
Group type: COMPARATOR
Intervention: Pre-filled syringe
Number of subjects: 421
Study 21180005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Silicacoating amalgam, etching dentin, silane application on amalgam, primer/bonding on dentin, opaquer on amalgam, resin composite on both
Number of subjects: 50
Study 21180005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Etching dentin, silicacoating amalgam, silane application on amalgam, primer/bonding on dentin, opaquer on amalgam, resin composite on both
Number of subjects: 50
Study 21180005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Etching dentin, primer/bonding on dentin, opaquer, resin composite
Number of subjects: 50
Study 21180005 — intervention group
Group type: COMPARATOR
Intervention: Group 4: Silicacoating, silane application, opaquer, resin composite
Number of subjects: 50
Study 21180005 — intervention group
Group type: COMPARATOR
Intervention: Group 5: Opaquer, resin composite
Number of subjects: 50
Study 17428114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2, 4, or 8 mg tablets once daily)
Number of subjects: 2595
Study 17428114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2595
Study 16919576 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB reference file
Number of subjects: 49
Study 16919576 — intervention group
Group type: COMPARATOR
Intervention: General reference database
Number of subjects: 49
Study 11860415 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg b.d.), Clarithromycin (500 mg b.d.), Amoxicillin (1 g b.d.)
Number of subjects: 84
Study 11860415 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.), Bismuth subsalicylate (600 mg q.d.s.), Metronidazole (400 mg t.d.s.), Tetracycline (500 mg q.d.s.)
Number of subjects: 84
Study 11860415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 84
Study 10457580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 61
Study 10457580 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 61
Study 7615102 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) - 1,000 micrograms intranasal buserelin acetate daily for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Number of subjects: 30
Study 7615102 — intervention group
Group type: COMPARATOR
Intervention: Placebo - no active treatment for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Number of subjects: 30
Study 2798990 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin (50 mg bid)
Number of subjects: 10
Study 2798990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid)
Number of subjects: 10
Study 2798990 — intervention group
Group type: COMPARATOR
Intervention: Pre-study
Number of subjects: 10
Study 299896 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (4 gm/day)
Number of subjects: 14
Study 299896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (2.4 gm/day)
Number of subjects: 14
Study 299896 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (14 days prior to each period)
Number of subjects: 14
Study 30592553 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxerol (325 mg acetaminophen and 150 mg ibuprofen per tablet) at low dose (1 tablet), mid dose (2 tablets), and high dose (3 tablets) for 14 days
Number of subjects: 0
Study 30592553 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxerol (high dose)
Number of subjects: 0
Study 30592553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30592553 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Paxerol and placebo)
Number of subjects: 0
Study 28941152 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-loading protocol
Number of subjects: 39
Study 28941152 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading protocol
Number of subjects: 39
Study 25495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTO)
Number of subjects: 333
Study 25495209 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 333
Study 25495209 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 333
Study 23619906 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (250 mg magnesium oxide daily for 8 weeks)
Number of subjects: 74
Study 23619906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 21899409 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAS with the use of the Wingspan stent system
Number of subjects: 451
Study 21899409 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management alone
Number of subjects: 451
Study 21899409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 451
Study 19255381 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary diagnostic facility
Number of subjects: 230
Study 19255381 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study 16924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate solution
Number of subjects: 60
Study 16924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate hydrogel
Number of subjects: 60
Study 16924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching + 20% sodium ascorbate hydrogel
Number of subjects: 60
Study 16924991 — intervention group
Group type: COMPARATOR
Intervention: Bleaching (10% carbamide peroxide gel)
Number of subjects: 60
Study 15020394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy by a research GP near their home address
Number of subjects: 151
Study 15020394 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 151
Study 16808802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (25 mg/day)
Number of subjects: 54
Study 16808802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10561343 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy (cisplatin 80 mg/m² on days 1 and 29, vindesine 3 mg/m² on days 1, 8, 29, and 36, mitomycin 8 mg/m² on days 1 and 29, RT starting on day 2 at 28 Gy)
Number of subjects: 320
Study 10561343 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 320
Study 10561343 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (same chemotherapy but RT initiated after completing CT at 56 Gy)
Number of subjects: 320
Study 10561343 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy
Number of subjects: 320
Study 7495243 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg)
Number of subjects: 29133
Study 7495243 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 7495243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study 1789063 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day
Number of subjects: 20
Study 1789063 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms levothyroxine and 100 micrograms iodide/day
Number of subjects: 20
Study 1789063 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms iodide/day (initial treatment) followed by 100 micrograms levothyroxine and 100 micrograms iodide/day (combination treatment)
Number of subjects: 20
Study 7011035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (2 million IU of penicillin G intramuscularly before and after the procedure, followed by 350 mg of pivampicillin three times daily for 4 days)
Number of subjects: 493
Study 7011035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 7011035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 493
Study 29779440 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive inferential style training
Number of subjects: 0
Study 29779440 — intervention group
Group type: COMPARATOR
Intervention: Negative inferential style training
Number of subjects: 0
Study 30177038 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hr for ≤96 h antenatally)
Number of subjects: 9
Study 30177038 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC
Number of subjects: 9
Study 26808546 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib in addition to gemcitabine
Number of subjects: 480
Study 26808546 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (placebo)
Number of subjects: 480
Study 26808546 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 480
Study 24115735 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation cohort (n=504)
Number of subjects: 11288
Study 24115735 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=492)
Number of subjects: 11288
Study 24115735 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk algorithm model
Number of subjects: 11288
Study 24115735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality risk prediction
Number of subjects: 11288
Study 23075043 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based social norms intervention with individualized social norms feedback after 5 months.
Number of subjects: 1000
Study 23075043 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1000
Study 20484334 — intervention group
Group type: EXPERIMENTAL
Intervention: Short breastfeeding duration (4 months)
Number of subjects: 768
Study 20484334 — intervention group
Group type: COMPARATOR
Intervention: Long breastfeeding duration (median 16 months)
Number of subjects: 768
Study 20484334 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with low baseline BMI
Number of subjects: 768
Study 17397408 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 87
Study 17397408 — intervention group
Group type: COMPARATOR
Intervention: Non-methane producers
Number of subjects: 87
Study 17397408 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane production
Number of subjects: 87
Study 16339586 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant modified vaccinia Ankara
Number of subjects: 0
Study 12122904 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0
Study 12122904 — intervention group
Group type: COMPARATOR
Intervention: Conventional neonatal intensive care
Number of subjects: 0
Study 9874045 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 212
Study 9874045 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 212
Study 8752486 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy in children
Number of subjects: 149
Study 8752486 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulo-palato-pharyngoplasty, midline laser grossectomy, or nasal surgery in adults
Number of subjects: 149
Study 2231833 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg flumazenil (group 1)
Number of subjects: 72
Study 2231833 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flumazenil (group 2)
Number of subjects: 72
Study 2231833 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg flumazenil (group 3)
Number of subjects: 72
Study 2231833 — intervention group
Group type: COMPARATOR
Intervention: 1 mg flumazenil (group 4)
Number of subjects: 72
Study 2231833 — intervention group
Group type: EXPERIMENTAL
Intervention: flumazenil (group 5)
Number of subjects: 72
Study 2231833 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flumazenil
Number of subjects: 72
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Core cooling by 1.0°C
Number of subjects: 12
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Core heating by 1.5°C
Number of subjects: 12
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia (PET,O2 = 50 mm Hg)
Number of subjects: 12
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Core cooling and heating after acclimatisation to 4330 m
Number of subjects: 12
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time with heating
Number of subjects: 12
Study 31696936 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time with cooling
Number of subjects: 12
Study 30554300 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory practice condition
Number of subjects: 358
Study 30554300 — intervention group
Group type: COMPARATOR
Intervention: Health education condition
Number of subjects: 358
Study 30554300 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 358
Study 28756115 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus reuteri)
Number of subjects: 30
Study 28756115 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 26786311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Number of subjects: 3925
Study 26786311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3925
Study 24163081 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized P2 receptor blockade (pyridoxal‐5‐phosphate)
Number of subjects: 1
Study 24163081 — intervention group
Group type: COMPARATOR
Intervention: Control trial (normal saline)
Number of subjects: 1
Study 22699175 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (counseling-centered activities in small groups) for 6 weeks
Number of subjects: 61
Study 22699175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 61
Study 19596954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan plus chemotherapy
Number of subjects: 650
Study 19596954 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 650
Study 17584429 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30
Study 17584429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15086284 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224
Study 15086284 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224
Study 15086284 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224
Study 12204931 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (graded exercise)
Number of subjects: 114
Study 12204931 — intervention group
Group type: COMPARATOR
Intervention: Self-help group membership
Number of subjects: 114
Study 12204931 — intervention group
Group type: COMPARATOR
Intervention: Sickness benefit receipt
Number of subjects: 114